Immuron Limited announced CEO Steven Lydeamore's virtual presentation at the Emerging Growth Conference on May 7, 2026, with Exhibit 99.1 detailing the company's biopharmaceutical platform and products Travelan® and IMM-529.
Key takeaways
CEO Steven Lydeamore presented virtually at Emerging Growth Conference on May 7, 2026 (10:15-10:45 am US Eastern Time).
Immuron develops orally delivered polyclonal antibodies from hyper-immune bovine colostrum for infectious diseases.
Travelan® (IMM-124E) reduces risk of travelers’ diarrhea; listed in Australia (AUST L 106709), licensed in Canada (NPN 80046016), dietary supplement in US.
IMM-529 in development as adjunctive therapy for recurrent Clostridioides difficile infection, targeting Toxin B, spores, and surface proteins.
Presentation includes company overview, platform technology, and product details.
U.S. Sales of A$0.5 million, up 1% on prior year (up 13% on pcp).